BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31099295)

  • 1. The prognostic values of matrix metalloproteinases in ovarian cancer.
    Zeng L; Qian J; Zhu F; Wu F; Zhao H; Zhu H
    J Int Med Res; 2020 Jan; 48(1):300060519825983. PubMed ID: 31099295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of glutamate-ammonia ligase is associated with unfavorable prognosis in patients with ovarian cancer.
    Fan S; Wang Y; Zhang Z; Lu J; Wu Z; Shan Q; Sun C; Wu D; Li M; Sheng N; Xie Y; Zheng Y
    J Cell Biochem; 2018 Jul; 119(7):6008-6015. PubMed ID: 29575012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in serous ovarian cancer is not associated with LATS expression.
    Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
    Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
    Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calpain system protein expression and activity in ovarian cancer.
    Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?
    Ozel E; Peştereli HE; Simşek T; Erdoğan G; Karaveli FS
    Int J Gynecol Cancer; 2006; 16(2):549-55. PubMed ID: 16681724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EphA8 is a prognostic marker for epithelial ovarian cancer.
    Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
    Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors.
    Furuya M; Ishikura H; Ogawa Y; Kawarada Y; Shibata M; Fujimoto S; Yoshiki T
    Pathobiology; 2000; 68(6):239-44. PubMed ID: 11493755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
    Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
    Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial. Endometrioid epithelial ovarian cancer.
    Cibull ML; Karabakhtsian RG
    Cancer; 2008 May; 112(10):2108-11. PubMed ID: 18327815
    [No Abstract]   [Full Text] [Related]  

  • 14. Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
    De Donato M; Petrillo M; Martinelli E; Filippetti F; Zannoni GF; Scambia G; Gallo D
    Gynecol Oncol; 2017 Jul; 146(1):170-178. PubMed ID: 28495238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Vav3.1 as prognostic marker in endometrial cancer.
    Boesch M; Sopper S; Marth C; Fiegl H; Wiedemair A; Rössler J; Hatina J; Wolf D; Reimer D; Zeimet AG
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):2067-2076. PubMed ID: 30083818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer.
    Wilczyński M; Żytko E; Danielska J; Szymańska B; Dzieniecka M; Nowak M; Malinowski J; Owczarek D; Wilczyński JR
    Arch Gynecol Obstet; 2018 Mar; 297(3):741-748. PubMed ID: 29335784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.